Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fedratinib versus best available therapy in ruxolitinib-pretreated myelofibrosis
NL-OMON55615Phase 3Completed
- Sponsor
- Impact Biomedicines
- Start
- Mar 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of fedratinib in myelofibrosis (MF) (2 arms), sponsored by Impact Biomedicines. Primary endpoint: Spleen volume response rate. Started Mar 2020; status: completed.
02
Drugs
fedratinib
03
Conditions
myelofibrosis (MF)
Beyond the preview
Go deeper on NL-OMON55615.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON55615.